Boston Scientific (BSX) Osake Kurssi
Boston Scientific Kurssi
Liikevaihto on kasvanut 5,1 % vuodessa viimeisten 19 vuoden aikana 20,07 Mrd. USD:een. Osakekohtainen tulos on kasvanut 14,1 % vuodessa viimeisten 14 vuoden aikana. Boston Scientificn nettomarginaali on nyt 14,4 %, noussut 8,7 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 63,50 USD, eli yli nykyhintaa 52,7 %. 38 analyytikosta 30 suosittaa ostoa — kokonaiskonsensus on Osta.
Boston Scientific osakekurssi
Boston Scientific liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Boston Scientific -osakkeesta
The main competitors of Boston Scientific Corp in the market include Medtronic, Johnson & Johnson, Abbott Laboratories, and Edwards Lifesciences.
Boston Scientific Corp is a global medical technology company. Its business model revolves around developing innovative medical solutions that enhance patient care and healthcare outcomes. Boston Scientific Corp manufactures and markets a broad range of medical devices used in various specialties, such as cardiology, urology, endoscopy, and neuromodulation. The company's commitment to research and development enables it to introduce advanced technologies and therapies that address unmet clinical needs. Boston Scientific Corp also focuses on collaborations and partnerships to expand its product portfolio, improve access to healthcare, and provide high-quality medical devices to patients worldwide.
Boston Scientific Corp is primarily active in the medical equipment and supplies industry.
Boston Scientific Corp is a renowned medical technology company based in Marlborough, Massachusetts. Established in 1979, it has become a global leader in the development, manufacturing, and marketing of innovative medical devices. With a focus on advancing patient care, Boston Scientific Corp offers a wide range of products for various medical specialties, including interventional cardiology, urology, endoscopy, and neuromodulation. The company's history showcases its commitment to medical breakthroughs and improving the lives of patients worldwide. Boston Scientific Corp's dedication to cutting-edge technology and strategic acquisitions has allowed it to maintain a prominent position in the healthcare industry.
Boston Scientific Corp has achieved significant milestones throughout its history. Some notable achievements include the development of the Taxus Express, a groundbreaking drug-eluting stent that revolutionized the treatment of coronary artery disease. Additionally, the acquisition of Guidant Corporation strengthened Boston Scientific's position in the field of cardiac rhythm management. The company's innovative products, such as the Watchman Left Atrial Appendage Closure device, have provided improved treatment options for patients with atrial fibrillation. Boston Scientific Corp continues to innovate and make advancements in medical technologies, helping to improve patient outcomes worldwide.
Boston Scientific Corp is primarily present in several countries and regions worldwide. The company has a strong global presence, with significant operations in the United States, Europe, Asia-Pacific, Latin America, and the Middle East. Its diverse market reach spans across more than 130 countries, enabling Boston Scientific Corp to provide innovative medical solutions and technologies to a vast range of patients and healthcare professionals worldwide.
Boston Scientific Corp represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patients' lives, the company is committed to developing and delivering innovative medical solutions. Boston Scientific Corp's dedication to collaboration extends to its partnerships with healthcare professionals and institutions, helping to address unmet needs and improve patient outcomes. By prioritizing patient-centric care, the company ensures that its products and services are designed to provide effective and meaningful treatments. Boston Scientific Corp's continued commitment to innovation and collaboration underscores its mission to transform lives through medical advancements in a rapidly evolving healthcare landscape.
Analyytikot asettavat tällä hetkellä Boston Scientific-osakkeelle keskimääräisen tavoitehinnan 66,50 USD (mediaani: 63,50 USD), mikä merkitsee +59,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 38 analyytikkoarvioon.
38 analyytikkoa arvioi tällä hetkellä Boston Scientific-osaketta: 30 suosittaa ostoa, 8 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Boston Scientific-yhtiöltä 21,23 Mrd. USD liikevaihtoa ja 3,24 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Boston Scientific-osake noteerataan hintaan 37,13 EUR (41,58 USD).
Boston Scientific-osake (BSX) on listattuna 10 pörssissä, muun muassa: NYSE (BSX), London (0HOY.L), SIX (Zürich) (BSX.SW), XETRA (BSX.DE), Frankfurt (BSX.F), München (BSX.MU), Düsseldorf (BSX.DU), Wien (BSXC.VI).
The Boston Scientific Corporation is a medical technology company that specializes in the manufacturing and development of medical devices. The company was founded in Massachusetts in 1979 and operates globally today. Its business model includes various divisions that focus on different medical specialties. The Cardiac Rhythm Management division of Boston Scientific is involved in the manufacturing of devices for the treatment of heart rhythm disorders. This includes products such as implantable defibrillators, pacemakers, and accessories. The products in this division are of high quality and have an excellent track record in treating patients with severe heart problems. The Interventional Cardiology division of Boston Scientific specializes in the manufacturing of products used in the treatment of heart diseases. This includes balloon catheters, stents, and catheter ablation systems. These products are typically minimally invasive and allow for a quick restoration of normal heart rhythm in patients. The Interventional Radiology division of Boston Scientific is focused on the manufacturing of products for the diagnosis and treatment of vascular diseases. The company produces catheters, stents, and embolization accessories, among other things. Additionally, Boston Scientific is also specialized in the development of products for the treatment of chronic pain. The products in this division include implantable pain therapy systems, neurostimulators, and accessories. These devices can alleviate patients' pain and improve their quality of life. The company is also specialized in the field of urology, including products for the treatment of conditions such as urinary incontinence and benign prostatic hyperplasia. Boston Scientific produces mesh implants and devices aimed at improving bladder control. Furthermore, the company has a division dedicated to gastrointestinal diseases, including products for the treatment of conditions like colorectal cancer and gastrointestinal bleeding. The portfolio includes endoscopes, balloon catheters, and other devices for the treatment of digestive tract disorders. Boston Scientific is committed to providing its customers with the best products. Product development is strongly focused on meeting the needs of patients and doctors. By continually developing new products, the company can expand its market position and maintain its leading position in the medical technology industry.
odotettu liikevaihto Boston Scientific on 21,23 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Boston Scientific on 4,85 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Boston Scientific:n hinta-voitto-suhde (P/E) on tällä hetkellä 12,83. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Boston Scientific-osakkeen arvostusta.
Boston Scientific:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,93. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Boston Scientific-osakkeen arvostuskennuslukuna.
Boston Scientific:n Eulpool-laatuscore on 5/10.
Boston Scientific:n ISIN on US1011371077. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Boston Scientific:n WKN on 884113. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Boston Scientific:n ticker on BSX. Tämä pörssinoteeraus käytetään Boston Scientific-osakkeiden kauppaan pörssissä.
Boston Scientific osake
Boston Scientific vertaisryhmä
Boston Scientific Ticker
Boston Scientific FIGI
Kaikki tunnusluvut ja syvällinen analyysi Boston Scientific:sta
Meidän osakeanalyysimme Boston Scientific-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Boston Scientific:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: